What's new? Log in Free sign up

Xencor (XNCR)

Company Profile

Company profile

Ticker

XNCR

Exchange

Website

CEO

Dr. Bassil I. Dahiyat Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • AbbVie • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Bausch Health Companies • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Gale Therapeutics Inc. ...

IRS number

201622502

XNCR stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Submission of Matters to a Vote of Security Holders

Quarterly report

7 May 25

Xencor Reports First Quarter 2025 Financial Results

Regulation FD Disclosure

Annual report to shareholders

Additional proxy soliciting materials

Definitive proxy

Changes in Registrant's Certifying Accountant

Xencor Appoints Todd Simpson to Board of Directors

Changes in Registrant's Certifying Accountant

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Alan Bruce Montgomery

Barbara Klencke

KURT A GUSTAFSON

KEVIN CHARLES GORMAN

RICHARD J RANIERI

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart XNCR financial data

Quarter (USD)	Mar 25	Dec 24	Sep 24	Jun 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	39.96 mm	39.96 mm	39.96 mm	39.96 mm	39.96 mm	39.96 mm
Cash burn (monthly)	434.33 k	(no burn)	16.09 mm	18.07 mm	5.41 mm	13.46 mm
Cash used (since last report)	1.12 mm	n/a	41.64 mm	46.77 mm	14.00 mm	34.85 mm
Cash remaining	38.83 mm	n/a	-1.69 mm	-6.81 mm	25.96 mm	5.11 mm
Runway (months of cash)	89.4	n/a	-0.1	-0.4	4.8	0.4

Beta Read what these cash burn values mean

Financial data from Xencor earnings reports.

Institutional ownership, Q4 2024

XNCR institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	193	209	-7.7%
Opened positions	26	39	-33.3%
Closed positions	42	28	+50.0%
Increased positions	81	58	+39.7%
Reduced positions	53	81	-34.6%

13F shares	Current	Prev Q	Change
Total value	1.59 tn	1.33 tn	+19.0%
Total shares	75.46 mm	72.42 mm	+4.2%
Total puts	4.20 k	7.90 k	-46.8%
Total calls	1.70 k	2.50 k	-32.0%
Total put/call ratio	2.5	3.2	-21.8%

Largest owners	Shares	Value	Change
BlackRock	12.20 mm	$280.39 bn	+10.6%
Primecap Management	8.98 mm	$206.46 bn	-1.7%
Vanguard	8.02 mm	$184.24 bn	+5.5%
EcoR1 Capital	6.14 mm	$141.21 bn	+15.3%
T. Rowe Price	4.04 mm	$92.76 mm	+2.7%
STT State Street	3.20 mm	$73.56 bn	+2.6%
TCG Crossover Management	2.45 mm	$56.35 bn	+1.0%
RTW Investments	2.40 mm	$55.22 bn	+317.9%
BVF	2.29 mm	$52.60 bn	+169.3%
Point72 Asset Management	2.18 mm	$50.03 bn	-30.2%

Largest transactions	Shares	Bought/sold	Change
RTW Investments	2.40 mm	+1.83 mm	+317.9%
BVF	2.29 mm	+1.44 mm	+169.3%
Millennium Management	0.00	-1.41 mm	EXIT
BlackRock	12.20 mm	+1.17 mm	+10.6%
Point72 Asset Management	2.18 mm	-943.15 k	-30.2%
EcoR1 Capital	6.14 mm	+814.35 k	+15.3%
UBS UBS	892.28 k	+802.82 k	+897.4%
Nuveen Asset Management	837.08 k	+685.56 k	+452.4%
Finepoint Capital	660.00 k	+660.00 k	NEW
BAC Bank of America	33.51 k	-585.93 k	-94.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

XNCR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Jun 25	Ranieri Richard J	Common Stock	Sell	Dispose S	No	Yes	9.22	2,993	27.60 k	19,183
16 Jun 25	Feigal Ellen	Common Stock	Sell	Dispose S	No	Yes	9.22	2,993	27.60 k	19,183
16 Jun 25	Gorman Kevin Charles	Common Stock	Sell	Dispose S	No	Yes	9.22	3,173	29.26 k	18,905
16 Jun 25	Gustafson Kurt A	Common Stock	Sell	Dispose S	No	Yes	9.22	2,993	27.60 k	20,183
12 Jun 25	Ranieri Richard J	Common Stock	Grant	Acquire A	No	No	0	13,686	0.00	22,176
12 Jun 25	Ranieri Richard J	Stock Option Common Stock	Grant	Acquire A	No	No	9.43	27,372	258.12 k	27,372
12 Jun 25	Simpson Todd E	Common Stock	Grant	Acquire A	No	No	0	13,686	0.00	13,686
12 Jun 25	Simpson Todd E	Stock Option Common Stock	Grant	Acquire A	No	No	9.43	27,372	258.12 k	27,372
12 Jun 25	Feigal Ellen	Common Stock	Grant	Acquire A	No	No	0	13,686	0.00	22,176
12 Jun 25	Feigal Ellen	Stock Option Common Stock	Grant	Acquire A	No	No	9.43	27,372	258.12 k	27,372

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's After-Market Session

Barclays Maintains Underweight on Xencor, Lowers Price Target to $6

Barclays analyst Peter Lawson maintains Xencor (NASDAQ:XNCR) with a Underweight and lowers the price target from $22 to $6.

Xencor Q1 EPS $(0.66) Misses $(0.60) Estimate, Sales $32.73M Beat $22.41M Estimate

Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.60) by 10 percent. This is a 40.54 percent increase over losses of $(1.11) per share from the same

'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study Of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody For Treatment Of Inflammatory Bowel Disease

Press releases

From Benzinga Pro

Xencor Reports First Quarter 2025 Financial Results

-- Recent interim Phase 1 study results for XmAb942 (Xtend™ anti-TL1A) support a 12-week maintenance dosing interval in XENITH-UC, a Phase 2b study in participants with ulcerative colitis, to begin in the second

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

-- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.